According to the NCI website, selinexor is an orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)
Indikation gemäss NCI Eebsite:
- Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used with dexamethasone in adults who have received at least four previous treatments that included at least two proteasome inhibitors, at least two immunomodulating agents, and an anti-CD38 monoclonal antibody.
This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that selinexor provides a clinical benefit in these patients.
A Global Randomized Trial Planned for Selinexor to Treat COVID-19
More Information in English:
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute